Jump to content


Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary

  • Please log in to reply
No replies to this topic

#1 gerry


    Advanced Member

  • Members
  • PipPipPip
  • 1,034 posts

Posted 17 November 2014 - 10:48 PM

East Hanover, NJ, May 14, 2014 -- Novartis Pharmaceuticals Corporation has settled its litigation with a subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec® (imatinib mesylate), which expire in 2019 (including pediatric exclusivity). The basic compound patent for Gleevec expires in the U.S. on July 4, 2015.

As a result of the settlement, Novartis will permit Sun Pharma's subsidiary to market a generic version of Gleevec in the United States on February 1, 2016. The terms of the settlement agreement are otherwise confidential. Sun Pharma's subsidiary has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of imatinib mesylate.


Novartis settles patent litigation on Gleevec (imatinib mesylate) with Sun Pharma subsidiary.pdf

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users